Strategies for Successfully Diagnosing and Treating Tardive Dyskinesia: Enlisting the Help of Caregivers, Improving the Lives of Patients
June 4, 2021
June 4, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Medical Education Resources and CMEology.
Supported by an educational grant from Neurocrine Biosciences, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of psychiatrists as well as advanced practice psychiatry clinicians who have an opportunity to care for patients with tardive dyskinesia.
At any given time, roughly 1 of every 4 patients taking antipsychotics experiences tardive dyskinesia (TD), a debilitating condition characterized by involuntary movements of the tongue, lips, face, trunk, and extremities. Fortunately, effective pharmacologic treatments for TD are now available. However, it can be challenging for clinicians to assess patients for TD, keep up to date on new agents, and create personalized treatment plans that facilitate long-term treatment success. In this activity, an expert faculty member will discuss the burden of TD on patients and their caregivers; TD risk factors; TD assessment and diagnosis strategies, including for virtual visits; and TD prevention and treatment options. Throughout, approaches for optimizing TD diagnosis and treatment by engaging caregivers in the therapeutic alliance will be discussed. Three videos will be used to illustrate the patient perspective on TD, the caregiver perspective on TD, and an expert’s approach to TD screening and monitoring.
The goal of this activity is to enhance the knowledge and competence that clinicians need to successfully diagnose and treat tardive dyskinesia, including strategies for enlisting the help of caregivers, to ultimately improve the lives of both patients and the people who care for them.
Upon completion of this activity, participants should be better able to:
- Demonstrate knowledge of the prevalence of TD among patients taking dopamine antagonists
- Explain the effect that TD has on patients’ quality of life and ability to function, as well as on caregivers’ wellbeing
- Identify strategies to promptly detect and diagnose TD that can be integrated into a busy practice
- Describe approaches that promote the long‐term success of TD treatment plans
Joseph P. McEvoy, MD
Case Distinguished Chair in Psychotic Disorders
Professor of Psychiatry
Department of Psychiatry and Health Behavior
Medical College of Georgia
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and CMEology. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
Physician Credit Designation
Medical Education Resources designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit Designation
Medical Education Resources designates this activity for a maximum of 1.0 ANCC nursing contact hour. Nurses will be awarded contact hours upon successful completion of the activity.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.
Disclosures of Conflicts of Interest
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Joseph P. McEvoy, MD
- Grant/Research Support: Alkermes, Biogen, Boehringer Ingelheim, Takeda Pharmaceuticals U.S.A.
- Consulting Fees: Intra-Cellular Therapies, Sunovion Pharmaceuticals Inc.
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Instructions for Participation and Credit
There are no fees for participating in and receiving credit for this activity. During the period TBD through TBD, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better, with no more than 3 attempts.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.